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ABSTRACT
This paper explores and develops the concept of ‘readiness’ as it relates to
the adoption of innovation. In particular, the paper discusses readiness in
regard to the notion of ‘technology readiness’ levels, widely used today by
both producers and users to monitor and manage emergent innovation.
The paper argues that, while useful, this notion needs to be informed by
and subsumed within a broader concept of ‘institutional readiness’. The
latter is especially important in conceptualising how new technologies
are actually adopted in organisational settings. The paper develops a
model of institutional readiness that recognises the saliency of
technology readiness but which embeds it within a broader socio-
technical framework. This is illustrated with reference to the emerging
ﬁeld of regenerative medicine.
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Introduction
The challenge associated with novel technology and its adoption is one that has ﬁgured for many years
in the policy domain. It is often argued, especially in the UK context but also elsewhere (e.g. ACOLA
2015), that innovation systems can be highly generative of new technologies but equally very poor
in ensuring they are taken up and implemented at scale within national settings (Edquist 1997).
It is this concern over the failure of innovative ideas and technologies to be successfully deployed
that has generated the extensive literature on the challenge of adoption and implementation (see
review by Nilsen 2015), which often makes references to the ‘valley of death’ (Butler 2008), the pro-
blems of market failure (Martin and Scott 2000) and the ‘barriers’ (e.g. Antoniou and Ansoﬀ 2004;
Baldwin and Lin 2002; Meijer 2015; Mohnen et al. 2008) working against technological innovation
and its ‘diﬀusion’ (Rogers 1995). Similar concerns underpin the perceived need for agencies facilitat-
ing technology transfer (Rogers, Takegami, and Yin 2001), and the widely used notion today of tech-
nology ‘translation’. Not surprisingly, within science and technology policy, we see a wide variety of
initiatives designed to bridge between the supply of and the demand for innovation, including the
establishment of dedicated translational centres (Edler and Yeow 2016).
In many ways these arguments and policy initiatives suggest a strongly held view that there is a
lack of receptivity for new technologies. The explanations for this vary. Most of these commentaries
contrast a person’s or group’s preparedness to be innovative with being risk-averse or cautious about
new ideas (see e.g. Elliott, Hall, and Meng 2008; Khalil 2011; Kuo, Liu, and Ma 2013; Rojas-Méndez,
Parasuraman, and Papadopoulos 2017). Elsewhere, contributions in management studies focus on
the organisational receptivity for new technology (whether that technology be incremental or
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radical in nature) that stress the need in particular for ‘change managers’ to open a pathway for adop-
tion (Shaw 2012).
It is then somewhat surprising that these contributions have failed to engage with and consider
the merits of the concept of ‘technology readiness’, since this idea, initially developed over forty years
ago in the USA, is primarily about how to prepare a new technology such that it is made ready for its
deployment in a very speciﬁc (organisational) setting. It involves a detailed and highly deliberate
process for determining the technology readiness level (TRL) of an innovative product (or practice)
and the range of material and informational resources needed to develop the product to completion.
As such, in principle such an approach should help to address some if not all of the concerns outlined
above. What is even more surprising is that, though relatively ignored in the academic literature, TRLs
are routinely used today in diﬀerent industrial sectors in gauging the development and prospective
market value of innovative developments, and as a touchstone by those accessing or buying-into
such innovation as markers of utility and reliability. They are also used by funding agencies when
advising developers and innovators on how their products need to be de-risked as they move up
the TRLs (e.g. EPSRC 2018).
In light of this, it seems important to look at TRLs more closely from within a science, technology
and innovation studies (STS) perspective, in order to both unpack the concept more fully, and to
determine how it might beneﬁt from being anchored in an STS-informed understanding of the
context of readiness itself. This takes us away from the concept of ‘barriers to innovation’ which
often carries negative connotations in regard to users’ conservatism in response to supply-side inno-
vation. Rather, readiness looks at the speciﬁc contexts within which innovation is engaged with and
made sense of, and how, in doing so, is often adapted in order to be adopted. It also moves away
from seeing technological innovation as an object or process that has a deﬁned and stable set of
properties which must be embraced by users: instead, innovations are re-conﬁgured by users as
part of their ‘normalisation’ (May et al. 2011).
The principal questions this paper asks are what can we learn from exploring the relationship
between technology readiness and work in STS which has examined the context of application of
innovation; and, can we build a more nuanced model of technology/institutional readiness that
draws on both? In doing so we move from an emphasis on the TRL’s supply-side perspective to
one that gives equal weight to the user-side perspective. The paper begins with an account of the
origin of TRLs, then moves on to discuss their use and limitations before discussing the contrasting
notion of institutional readiness. The term ‘institutional readiness’ has been used in speciﬁc ﬁelds (e.g.
philanthropic studies) to explore ﬁeld-speciﬁc organisational features are likely to increase the
‘success’ of an organisation (Barnes and Brayley 2007). Here, we develop a concept of IR that is theor-
etically grounded in STS and innovation studies, and we show how it can be usefully aligned with
TRLs through drawing on empirical material from a recently completed research project that has
examined the emergence of regenerative medicine. We conclude by arguing for a more complex
but thereby more serviceable account of ‘readiness’.
Technology readiness levels: origins and use
The TRL concept, which can be traced back to 1974, has its origins in NASA and subsequently the US
DoD, used to monitor the progress of space and defence programmes to ensure any risks are known
and manageable (though clearly in light of a number of tragic events, not always successfully so).
Since then it has been widely embraced and enshrined in criteria that evaluate an emergent inno-
vation in terms of its ‘technology readiness level’. There are nine TRLs, from initial conception of
an idea through to its deployment and actual use (see Figure 1), thus passing through levels
which indicate signiﬁcant steps as the technology ‘matures’. This involves increasingly real-time
demonstrator stages that validate the technology within its envisaged environment (such as
within spacecraft). Technology adoption is thus a series of sign-oﬀs to move through one risk-gate
to the next and integrate innovation within a developing technology regime or system. Typically
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this involves the approval of both hardware and software elements at ever higher levels of speciﬁcity
in terms of their material conﬁguration and performance (Lee, Chang, and Chien 2011).
TRL assessment commands considerable inﬂuence in innovation policy and procurement. For
example, in the US, the Federal Aviation Authority and the Department of Energy use TRLs to
assess and triage prospective technology developments, while in the UK the Nuclear Decommission-
ing Authority uses TRLs to assess component systems being prepared for decommissioning plants
(NDA 2014). The European Commission’s Horizon 2020 research programme (European Commission
2015) has also recently adopted TRLs within its COSMOS space research network. Given the context
within which TRL modelling has developed, it is no surprise that its use has been principally in large-
scale, high cost and high-risk settings, such as the development of the Space Shuttle (Mankins 2009).
But it has not been restricted to these settings: elsewhere, TRLs have been adopted and adapted to
serve more medium range/scale needs by international agencies (such as the OECD [Ekins 2010]),
government departments, large companies and innovation agencies promoting early stage
product development, such as the Cell and Gene Therapy Catapult in the UK (C&GTC 2017), to deter-
mine whether moves towards the market/end users by emerging products are likely to be timely, and
technically and economically robust, as well as risk-managed.
Related approaches, though not using the language of TRLs as such, can be found in national
public bodies that seek to embed emerging innovation within their constituent organisations. For
example, US hospitals have adopted the Healthcare Information and Management Systems
(HIMSS) Programme. This was originally concerned with appropriate digital standards, and is now
used to deﬁne how digital systems meet speciﬁc organisational needs and at the same time how hos-
pitals need to adjust to deploy new IT systems: HIMSS Level 7 is the current target for leading US hos-
pitals. The UK’s NHS has adopted a slimmed down version of this via its ‘Digital Maturity Index’ (NHS
2018).
As a technology management tool, technology readiness assessment is conducted at diﬀerent
stages in a developing technology system to determine its technical and economic costs, prospec-
tive economic value and possible risks. The TRLs also act to provide a common framework or man-
agement platform through which a very diverse range and large numbers of actors – designers,
regulators, funding agencies, engineers etc. – can cooperate and communicate via shared TRL
standards.
Given its use in a diverse range of systems within which technology is being developed, pro-
cured, and readied for market, it is surprising that TRLs have had relatively little consideration
Figure 1. Technology readiness levels: NASA’s original deﬁnitions.
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in the ﬁeld of innovation studies. Indeed, the possible contribution that TRL analysis might make
is suggested by Nakamura, Kajikawa, and Suzuki (2012) who argue that the multilevel perspec-
tive (MPL) developed within innovation studies (Geels 2006; Kern 2012) should be complemen-
ted by a TRL approach. They argue that TRLs are useful in understanding how technologies are
developed in ﬁne-grained detail within a speciﬁc industrial sector, and how they might vary
within that. This points to an important aspect of TRL; namely its attention to the speciﬁc
material and technological characteristics of innovation, such as its component parts and their
integration. This might then be of value in the broader analysis of ‘emerging’ technologies
(Rotolo, Hicks, and Martin 2015).
At ﬁrst sight, then, the TRL approach which envisages speciﬁc settings wherein the technology will
be most eﬀectively (and least riskily) used, might be seen as a useful adjunct to work in innovation
studies. But this begs the question of how eﬀective it actually is as a ‘tool’ in practice. There has been
only one detailed qualitative analysis of the use of TRL by companies, provided by Olechowski, Eppin-
ger, and Joglekar (2015). They ﬁnd that there are three areas where problems arise in the application
of TRL which relate to ‘system complexity, planning and review, and validity of assessment’ (2084). In
brief, the ﬁrst relates in particular to questions they raise about the need to recognise the growing
complexity of a system as ‘levels’ combine and the discrete components become more plastic in
doing so at their interfaces, such that an overall ‘system measure’ is a more useful marker of a work-
able technology. The second points up the diﬃculties associated with failure to integrate the TRL
process within an organisation’s business model and processes, while the third draws attention to
the lack of precision in assessing TRLs and the ‘tests’ used to do so such that validation measures
are open to doubt.
Despite this TRLs are used to underpin decisions to invest, further develop and deploy new tech-
nology. Such decisions are based on metrics of risk and technical standards for discrete components
which are seen to conﬁrm the ‘maturity’ of a particular piece of equipment at a particular point in
time. What is important to note here is that the maturation process directly implies that the material
properties of a technology change over time as tests are carried out and risks reduced. However, TRL
also assumes that a technology/component is materially the same across diﬀerent contexts of use as
its materiality ‘matures’, otherwise there would be no basis for it to be signed-oﬀ at diﬀerent stages
for systemic use by multiple parties.
Despite their shortcomings TRLs at least direct attention to this materiality of technical systems –
components, tools, devices etc. – and their technical conﬁguration. They are, however, limited in
regard to the assumptions they make about how this conﬁguration comes about, its meanings
and practices, and in particular how we need to understand the inter-relation between multiple tech-
nologies (Nelson 1994) and the ‘natural and social factors’ that shape their development and adop-
tion. This requires an examination of those socio-technical processes associated with the
implementation and adoption of innovation.
Attention turns then to the milieu within which novel technologies are developing, being enabled,
embraced, marginalised or side-lined. It is this institutional domain and its practices, routines,
resources and values that determine what can be called ‘institutional readiness’ (IR). We propose
the term ‘institutional’ rather than simply ‘organisational’ because we want to stress both the
intra- and extra-organisational dynamics that shape the ways in which innovative technologies are
given meaning, adopted and implemented. DiMaggio and Powell (1983) coined the phrase ‘insti-
tutional life’ which points us in this direction, suggesting a broad range of interacting processes
and practices found within and between related organisations (such as public-private networks, regu-
latory agencies and materials suppliers) at a ﬁeld level. The substantive aspects of this will vary by
sector, as Malerba (2002) has argued, noting that diﬀerent sectors – say medicine, transport or
energy – have distinct ‘knowledge bases, technologies, inputs and demand’ (248). We now discuss
the IR concept and how and why this was developed, moving on to discuss its relation to TRLs
and exemplifying this through drawing on some of the empirical material from a major UK-based
research project on regenerative medicine.
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Developing the concept of institutional readiness
The concept of institutional readiness was developed through a research project the authors under-
took between 2014 and 2017 that explored the emergence of regenerative medicine (RM). This ﬁeld
has been associated with huge promise – notably the move from therapy to cure – and an ability to
tackle not merely rare diseases, where much of the early investment has been made, but more
common conditions, such as macular degeneration and diabetes. As a result, we have seen a rapid
growth in speculative, large-scale ﬁnancing, the creation of specialist research and clinical centres,
and new regulatory vehicles to help create a bio-clinical pathway for promising treatments. Recent
government reports in the Australia, the UK and USA describe the ﬁeld as ‘revolutionary’ and one
of the ‘8 Great Technologies’ shaping the future (Willetts 2013). State investment in the ﬁeld has
grown rapidly, such as in the UK, with investment in the Cell and Gene Therapy Catapult and its
new manufacturing centre near Stevenage, as well as three new Advanced Therapy Treatment
Centres linked to the Catapult which are funded by Innovate UK to the tune of £30 m over 5 years
from 2018 (Innovate UK 2018).
Despite the promise and levels of support being received, our research, which drilled down into
the ﬁeld through extensive empirical ﬁeldwork over three years (authors’ REF/anon),1 identiﬁed three
speciﬁc challenges not found elsewhere in other novel ﬁelds of biomedicine. All novel therapies have
to confront similar issues such as their perceived utility, novelty, regulatory burden (such as conform-
ing to Good Manufacturing Practice [GMP]), cost, and skill demands. Regenerative medicine however,
encounter three additional challenges relating to the stabilising of live tissue (the cell lines) at quality
thresholds that meet clinical standards, scaling up and manufacturing the many trillions of cells
needed for patient therapies without losing eﬃcacy or quality of the cell lines, and ﬁnding the
right regulatory framework for this form of medicine beyond the conventional pharmaceutical
models which have driven most of the regulatory agenda this past 40 years. Such challenges are
speciﬁc to RM given its whole basis is the identiﬁcation, manipulation, scaling up and deployment
in the clinic of live tissue, sometimes derived from the patient (autologous) or from others
(allogeneic).
In exploring these speciﬁc RM challenges it became clear that the actual promise of the therapy
would depend on understanding the innovation pathways driving corporate investment and how
these would ultimately relate to existing, and the possible need for new, clinical adoption processes.
The speciﬁcity of the ﬁeld was recognised by the UK government which established a RM ‘expert
group’ (REF) (one of the authors was a member of the group) which called for new approaches to
be considered in regard to appropriate forms of regulation and experimental forms of reimburse-
ment (to be met by the NHS for the costs of using early, experimental forms of treatment).
However, there was little or no attention given in this policy-related work to the granularity of clinical
adoption in hospitals and what sort of organisational changes, resources, and new practices might be
needed there. For example, the Catapult, a key driver of the industrial application of RM and promoter
of new products, saw its remit as lying outside of the clinic, and indeed its contractual terms with
government reinforced this boundary.
This question of how might clinical adoption be achieved can be partly addressed through
drawing on related studies within STS and medical sociology. Previous work has examined in
detail those factors that aﬀect take-up (Greenhalgh et al. 2015) and adoption (Ulucanlar et al.
2013). These show that technology never speaks for itself, neither does evidence (or evidentiary
claims), but rather organisational practices, localised values and professional interests, alongside
limited resources, are key in determining implementation and adoption. Moreover, as May et al.
(2011) have shown through the development of ‘normalisation process theory’, what implementation
means in practice depends on the play of processes that enable new technologies or techniques to
be normalised, or routinised in clinical (and indeed other) settings. Such settings or contexts should
not be seen as static, or in some sense (pre-)given but are process-driven, changing and reshaped
over time.
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Nevertheless, key players such as the UK’s Catapult use the TRL model to assess and determine the
readiness for RM products/therapies to be deployed in clinical settings. The Catapult’s subscription to
TRLs as a vehicle through which to triage promising but not yet ‘ready’ therapies plays a key role in
determining the support it gives to prospective ‘clients’, typically UK and potentially international
SMEs. As we saw above, TRLs do provide an important marker of the relative maturity of an inno-
vation and in their focus on risk assessment play a valuable role in assessing technical aspects that
are key (here) to safer medicine. This is allied to the regulatory framework provided by the UK regu-
latory authority, the Medicines and Healthcare products Regulatory Agency (MHRA).
What was needed then was a framework that could engage with the TRL model yet at the same
time locate that within an organisational context seen through the recent work on adoption referred
to above. To develop this, we sought to identify the key intra – and extra-organisational dimensions
that shape adoption and implementation processes, and as both play a role make a case for seeing
these in terms of not merely an organisational but an ‘institutional readiness’. Building on the
diﬀerent contributions made by STS and innovation studies literature discussed we have sought to
construct a broad model of readiness that includes both internal (such as routines, practices and
values) and external (such as standards and regulatory) processes. We outline the principal features
of the model in Figure 2 below.
These eight categories of IR and their operational deﬁnitions focus our attention on how new tech-
nologies are engaged with and made sense of through cultural processes and institutional structures
within and outside of speciﬁc organisations.
A central diﬀerence to the TRL model is that these categories are orthogonal to each other rather
than a sequence of ‘levels’ – one does not necessarily presuppose the other(s): it would be possible,
for example, for a hospital or similar clinical setting to show evidence for ‘adoptive capacity’ but not
necessarily have a strong strategic focus or formal evaluation processes in place. Clearly, the more of
these dimensions that are operant, the more one can argue that a speciﬁc organisation is institution-
ally readied (intra-and extra-organisationally) for innovation.
We can summarise here what we argue are the key features of IR compared with TRL. It is impor-
tant to do this if we are to ﬁnd a way of aligning them productively. Figure 3 below oﬀers such a
summative account.
Figure 2. Key aspects of institutional readiness.
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Our comparison here emphasises the main diﬀerences in analytical terms between the two
approaches. We have already commented on the ﬁrst three of these. In regard to the last two, the
IR approach draws attention to the ways in which the material and the social are co-produced.
From an STS perspective, (see e.g. Hoeyer 2013; Law 2010) materiality is deﬁned through the relation-
ship between things, and most importantly, as Law argues, ‘materials – technologies – are moulded
by the intersection of natural and social factors’. We can see materiality as an expression of what
Sørensen (2007) calls a ‘distributed eﬀect’ (45). For example, banked cell lines only perform as, i.e.
only become ‘lines’ for use where they meet biological quality, regulatory and ethical provenance
requirements, each recursively related to the other. This has implications for what we understand
as a test or a demonstration of TRL since, in this sense a test is an assessment of a distributed
eﬀect and how that is ‘read’ by diﬀerent actors involved with diverse interests. These may relate
to intellectual property, regulation and quality standards.
TRLs are then perhaps best understood as reﬂecting that ‘intersection’ Law speaks of, whereby the
material and its social framing andmeaning are enacted at each of the diﬀerent ‘Levels’. These cannot
though be seen to be completely elastic or open-ended, for the socio-material renders obdurate
boundary eﬀects too that make a technology workable and that makes ‘material sense’ with quite
speciﬁc aﬀordances (Hutchby 2003): the material shapes the social, and the social shapes the material
but not in an unbounded way. Here we begin to see how in regard to materiality TRLs and IR might be
constructively aligned.
In a similar and related fashion, the implementation of novel technologies typically requires trial
and error, or what Fleck (1994) has called ‘learning by trying’, but he goes further to argue that in this
process ‘signiﬁcant innovation [takes place] during implementation itself’ (638) inasmuch as getting
this ‘to work’ actually generates new insights about the innovative potential of a new technology. This
is distinct from the comparable concept in TRLs, namely, implementation as the incorporation of an
already ‘working’ technology. The assumption here is that users get to grips with the innovation
through ‘learning by doing’. The principal contrast between the two approaches is that of TRLs’
notion of a technically working technology and an IR approach which emphasises the workability
of a technology in a given context, and given Fleck’s commentary, one that has additional value
as a result. By paying attention to a technical conﬁguration that ensures that a working innovation
is one that is made workable through the practices of its users, we begin to see how implementation
carries both TRL and IR dimensions. Overall, this alignment encourages us to see assessment as a
socio-technical process. The question then is raised, how might this con-joint approach be used in
practice? We try to illustrate this below through drawing on our recently completed project on regen-
erative medicine.
An example from the ﬁeld of regenerative medicine
In the UK there has been a number of initiatives designed to increase the pace at which access to new
medicines occurs, as enshrined in the Accelerated Access Report (AAR 2016). Among the
Figure 3. Comparing IR and TRL.
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recommendations in the report was the identiﬁcation of what were called ‘transformative products’
that should be given special attention and support across government bodies, industry and the NHS.
A new ‘Accelerated Access Partnership’ (AAP), made up of a large and diverse range of stakeholders
would be created, responsible for identifying innovations that can be given a ‘transformative’ desig-
nation. They would be assisted in this process through engaging with existing and newly created Bio-
medical Research Centres based on university/hospital collaboration.
One outcome of this was the provision of £30 m of funding over 3 years from 2018 by the govern-
ment agency, Innovate UK, to support the establishment of three new ‘Advanced Therapy Treatment
Centres’ (ATTC). These will be the organisational sites which will have to encapsulate and address the
challenges noted above and so make regenerative medicine workable within the clinic. The proposed
ATTCs are in eﬀect pilots of central importance to the development of the ﬁeld. The centres will
provide key sites through which institutional readiness at the level of the organisation will be
crafted. This will include speciﬁc clinical competences, a role for relevant patient associations in pro-
viding patient input, the integration of diverse forms of data (beyond trials data, including evidence
from registries, hospital exemption, and compassionate use records [Papadaki 2017]), an alignment
between the new centres and existing rare-disease treatment centres, and strong links to regional cell
therapy product manufacturing sites (such as the CGTC). The centres will need to ensure that they
create additional knowledge and skills and leverage existing infrastructure, while being geographi-
cally accessible within the UK. The ways these are organised and coordinated will be key to creating
an adoptive capacity within, and longer term sustainability for, the ﬁeld, and especially how they can
be models for elsewhere in the clinical system beyond specialist treatment centres per se.
Earlier we gave a broad and rather abstract account of IR, and its main categorical dimensions.
Here we provide a more substantive account of IR as we interpret its role in the new ATTCs.
Figure 4 below, based on our ﬁeldwork, puts some ﬂesh on the IR concept.
We have sought to operationalise each of the IR categories as they would apply to a newly created
ATTC, identifying those key socio-technical processes and practices that will help to build readiness
for regenerative medicine. A range of social actors are included, not least relevant patient groups who
will share some of the burden of risk in their participation in clinical trials. Other key issues relate to
ensuring the skills base is developed and equally importantly a new data-collection infrastructure is
put in place to capture the supply, storage, use and clinical eﬀectiveness of cell lines. The challenges
above are made especially diﬃcult given that each of the ATTCs comprises a regional consortium of
players from clinical, academic through to corporate actors. Building the new ‘institutional logic’ for
the ATTCs will require new architectures of production, distribution and delivery that are stable and
integrated.
Discussion: aligning IR and TRLs
The development of new technologies poses technical, production and marketing challenges within
a wider regulatory and user-context which might – especially in more radical areas of innovation that
carry new uncertainties, such as regenerative medicine – be relatively unreceptive or even if not, still
lacking in institutional readiness to embrace, adopt and implement novel socio-technical systems.
The question remains then how might technology readiness levels relate to our characterisation of
institutional readiness? Does our initial critique mean that the TRL model should be abandoned?
The limitation of the TRL approach relates principally to its failure to make explicit the socio-tech-
nical infrastructure in which TRLs are embedded. The ‘risks’ they envisage as being under control (or
not) tend to be deﬁned in purely technical terms, whereas such risks are related to socio-technical
infrastructures. Whether we are talking about ‘complex’, emergent technologies or more mature
technologies, risks need to be understood in these terms. This means a ‘mature’ technology as
deﬁned solely in TRL terms may itself not be ‘ready’ for use in certain systemic conditions. Secondly,
readiness in TR terms relates to signing-oﬀ risks (as manageable/known) whereas IR is about a move
towards a broader understanding of (e)valuation, which encompasses perceived risks, beneﬁts,
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workability and crucially how these interact or are recursive. Moreover, TRL approaches fail to con-
sider how contexts change over time, and indeed presume ‘context’ itself is a ﬁxed, pre-given
state. Key here too is that a technology has to be understood as a tool/process/system that makes
sense only in relation to other technologies and institutional milieu.
What then might constitute a useful TRL/IR alignment? We illustrate this by discussing the TRL
level which is at the threshold of component scale-up across a technological system. This is TRL7,
viz. ‘Component validation in relevant environment’ (NASA 2007). There are two key terms here –
‘component validation’ and ‘relevant environment’. These two relate to the ‘demonstration’
process through which a novel technology can be assessed and seen to ﬁt the context of its appli-
cation. With regard to regenerative medicine, component validation is highly problematic since
the ‘components’ comprise manipulated cells that must be produced in single or multiple batches
to a quality level whose validation can only be determined through late Phase (Phase 3 +) clinical
trials, where controlling for endpoint and outcome measures in vivo is challenging and can only
be resolved via IR-related measures, especially those concerned with a data-collection infrastructure
for monitoring outcomes (see Figure 4).
This in turn relates to the ‘relevant environment’ within which the ‘component’ is assessed: as we
saw above in our discussion of the UK context, while the ‘environment’ for regenerative medicine has
begun to move towards a more enabling one in which a series of policy and funding initiatives have
helped to build momentum in the ﬁeld, it is still clear that the key clinical structures are yet to appear.
There will need to be an articulation between the provisionally ready technology, and the emerging
organisational framework that can handle uncertainties in the clinical adoption and use of regenera-
tive medicine therapies and that is likely to require a new overall accountability and risk framework,
as operationalised in the IR category related to the development of novel institutional structures to
do this (Figure 4). Without this, it is likely that there will be considerable diﬃculties in regard to
Figure 4. Developing IR within ATTCs.
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‘translational medicine’ and so likely non–adoption: in that regard, ‘clinical utility’ is a relational prop-
erty rather than intrinsic to the technology. If a technology is not workable (i.e. has low IR), it has little
utility.
Beyond this speciﬁc framing of a TRL/IR alignment at ‘Level 7’, there are a number of important
generic issues that need to be noted. First, TRL are sequential over time whereas IR categories are
not. What we want to suggest here is that the spatio-temporal points (TRLs) when boundaries to
the next level are to be crossed are those where TRL/IR alignment questions need to be asked, as
indicated in our discussion of TRL 7 above. This would help to ensure that a particular feature of a
technology does not become entrenched and subsequently generate major problems when
adopted in institutional settings. Secondly, TRLs are typically strongly quantitative measures of
risk/relative maturity of a product etc, whereas IR relates more to qualitative processes and practices.
The performative utility of TRLs should not be undermined by combining with IR: the alignment
would ensure a socio-technical consolidation of any speciﬁc TRL, so the risk calculus (the ﬁgures)
takes account of and anticipates the wider dimension. This is a more organisationally robust
approach. It is also worth noting that in the UK NICE (National Institute for Health and Care Excellence)
is emphasising the importance of qualitative evidence (in conjunction with quantitative data) for
making decisions about commissioning new products, and indeed healthcare commentators more
generally are calling for more qualitative evidence to inform implementation practices (e.g. Carroll
2017).
Finally, at each TRL/IR juncture the actors responsible will vary according to the speciﬁc challenges
that need addressing. IR is about marshalling trans-organisational expertise and participation in
helping to ‘ready’ diverse actors to undertake more workable, doable technological innovation.
This is why we speak of institutional and not ‘organisational’ readiness. In Level 7 discussed above,
the key actors in the ATTC will be those responsible for building an appropriate data infrastructure
and those staﬀ associated with quality assurance, GMP, trials design and monitoring outcomes.
These will be drawn from clinical research, technical support and commercial staﬀ. IR is about mar-
shalling trans-organisational expertise and participation in helping to ‘ready’ diverse actors to under-
take more workable, doable technological innovation.
Conclusion: theoretical and policy implications
The paper has developed a new model of institutional readiness in order to build on recent work in
STS and innovation studies that has examined the diﬃculties of adopting innovative technologies.
We suggest a range of core institutional characteristics that can be applied to any socio-technical
domain to determine what components are in place, need to be built, can be modiﬁed and so on
to create a framework through which innovations can be more likely to succeed. While the
speciﬁc features of the ﬁeld of regenerative medicine pose their own challenges for the TRL
model, the broader lesson is that in any ﬁeld of innovation which is disruptive of existing socio-tech-
nical approaches, the actual value of TRLs will depend on how well they incorporate a focus on (trans)
organisational integration.
Moreover, the IR framework is itself strengthened by opening up a conceptual dialogue with TRLs:
TRLs draw attention to and are premised upon understanding the material/technological develop-
ment of new products/processes. IR points up the contingencies here yet in doing so recognises
the need to understand and engage with the technical claims/practices that building new technol-
ogies requires.
The paper explored how this approach might be used in the example of the specialist ATTCs. That
raises the question of whether the work involved in TRL/IR alignment can only be undertaken in such
settings, i.e. those designed from the start with a sense of how best to deal with uncertain, emergent
technologies. We suggest that the role of specialist centres should be to determine what can be
black-boxed in regard to the IR/TRL assessment and so the (reduced human/technical) resources
needed to implement new technologies outside specialist centres where the early TRL/IR work is
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done. While the IR model is best seen to work most eﬀectively in contexts such as the Centres, lessons
learned therein can be generalised elsewhere and made relevant. This argument also enables us to
practice what we preach – i.e. that the IR approach cannot be parachuted in and made to work
without recognising the context that makes it most workable. This would also highlight where and
what capacity for innovation needs to be built elsewhere. This is a core issue that resonates with
the journal’s focus on both technology analysis and strategic management and indeed how the
two are co-related.
From a policy perspective, within or between organisations, those using TRLs should seek to
develop their assessments based on an understanding of the socio-technical ﬁeld’s IR proﬁle, and
so develop guidelines relating to readiness that are informed by this. In many ways this would
ensure sensitivity to the fact that any TRL assessment is a test of a distributed eﬀect that can be
‘read’ quite diﬀerently by those actors involved. We have shown how using both TRLs and IR can
provide the condition for an alignment of both a working and a workable technology.
Note
1. Fieldwork generated an extensive data set based on over 80 interviews with diverse actors in the area – research
scientists, clinicians, key regulatory and commercial agencies, and research procurement and management
groups in hospital and wider NHS contexts.
Disclosure statement
No potential conﬂict of interest was reported by the authors.
Funding
This work was supported by Economic and Social Research Council [grant number ES/L002779/1].
Data available on request due to privacy/ethical restrictions
The data that support the ﬁndings of this study are available on request from the corresponding author, AW. The data are
not publicly available due to [restrictions e.g. their containing information that could compromise the privacy of research
participants].
Notes on contributors
Andrew Webster is a member of Science and Technology Studies Unit (SATSU) and Department of Sociology at the Uni-
versity of York. He was Director of the £5 m ESRC/MRC Innovative Health Technologies Programme, is member of various
national Boards and Committees (including the UK Stem Cell Bank Steering Committee, and the Regenerative Medicine
Expert Group, and was Specialist Advisor to the House of Commons Health Select Committee). He was national co-ordi-
nator the ESRC’s £3.5 m Stem Cells Initiative (2005–9) and is PI on a £1.5 m ESRC-funded project on regenerative medi-
cine, ‘REGenableMED’. He is also Co-I on a recently started project exploring gene therapy, and collaborating with
colleagues at the University of Montreal on research relating to ‘responsible health innovation’. He is Co-Editor of the
Health Technology and Society Series published by Palgrave Macmillan. His recent books include The Global Dynamics
of Regenerative Medicine (2013) and he has published widely in social science and science journals. He was elected a
Fellow of the Academy of Social Sciences in 2006. He was Head of the Department of Sociology 2005–9 and Dean of
Social Sciences, 2009–13 at York. He is Co-Chair of the Association for Studies in Innovation, Science and Technology-UK.
John Gardner is based at Monash University in the School of Social Sciences. He has undergraduate degrees in both
Science and Social Science. In 2010 he was awarded a Wellcome Trust PhD Studentship in Sociology to explore an inno-
vative clinical team providing Deep Brain Stimulation to children and young people with severe movement disorders. In
2014 he joined the Science and Technology Studies Unit at the University of York, UK, to work on the ESRC-funded ‘REGe-
neableMED’ project exploring the social dynamics of innovation in regenerative medicine. He has published in a range of
social science and medical practitioner journals. His monograph, Rethinking the Clinical Gaze (Palgrave) draws on ethno-
graphic research of an innovative clinical team to examine the biopolitical implications of patient-centred medicine.
TECHNOLOGY ANALYSIS & STRATEGIC MANAGEMENT 1239
ORCID
John Gardner http://orcid.org/0000-0001-7417-348X
References
AAR (Accelerated Access Review). 2016. Final Report: Review of Innovative Medicines and Medical Technologies. London:
The Crown.
ACOLA. 2015. Technology and Australia’s Future: Final Report. Canberra: Learned Academies of Australia.
Antoniou, P. H., and H. B. Ansoﬀ. 2004. “Strategic Management of Technology.” Technology Analysis and Strategic
Management 16 (2): 275–291. doi:10.1080/09537320410001682928 [Taylor & Francis Online].
Baldwin, J., and Z. Lin. 2002. “Impediments to Advanced Technology Adoption for Canadian Manufacturers.” Research
Policy 31: 1–18.
Barnes, M. L., and R. E. Brayley. 2007. “Institutional Readiness and Grant Success among Public Recreation Agencies.”
Managing Leisure 11 (3): 139–150.
Butler, D. 2008. “Translational Research: Crossing the Valley of Death.” Nature 453: 840–842.
Carroll, C. 2017. “Qualitative Evidence Synthesis to Improve Implementation of Clinical Guidelines.” BMJ 359: j80.
C&GTC. 2017. https://ct.catapult.org.uk/resources/cell-therapy-catapult-preclinical-database/cell-and-gene-therapy-
catapult-uk-preclinical.
DiMaggio, P. J., and W. W. Powell. 1983. “The Iron Cage Revisited: Institutional Isomorphism and Collective Rationality in
Organizational Fields.” American Sociological Review 48: 147–160.
Edler, J., and J. Yeow. 2016. “Connecting Demand and Supply: The Role of Intemediation in Public Procurement of
Innovation.” Research Policy 45 (2): 414–426.
Edquist, C., ed. 1997. Systems of Innovation. London: Routledge.
Ekins, P. 2010. Environmental and Eco-Innovation: Concepts, Evidence and Policies. Paris: OECD.
Elliott, K., M. C. Hall, and J. Meng. 2008. “Student Technology Readiness and its Impact on Cultural Competency.” College
Teaching Methods & Styles Journal (CTMS) 4 (6): 11–22.
EPSRC. 2018. The Funding Landscape. Swindon, UK: Engineering and Physical Sciences Research Council. https://epsrc.
ukri.org/research/ourportfolio/themes/healthcaretechnologies/strategy/toolkit/landscape/.
European Commission. 2015. Horizon 2020: The EU Framework Programme for Research and Innovation. http://ec.
europa.eu/programmes/horizon2020/en.
Fleck, J. 1994. “Learning by Trying: The Implementation of Conﬁgurational Technology.” Research Policy 23 (6): 637–652.
Geels, F. W. 2006. “Co-evolutionary and Multi-Level Dynamics in Transitions: The Transformation of Aviation Systems and
the Shift from Propeller to Turbojet (1930–1970).” Technovation 26: 999–1016.
Greenhalgh, T., R. Procter, J. Wherton, P. Sugarhood, S. Hinder, and M. Rounceﬁeld. 2015. “What is Quality in Assistive
Living Technology? The ARCHIE Framework for Eﬀective Telehealth and Telecare Services.” BMC Medicine. doi:10.
1186/s12916-015-0279-6.
Hoeyer, K. 2013. Exchanging Human Bodily Material: Rethinking Bodies and Markets. London: Springer.
Hutchby, I. 2003. “Aﬀordances and the Analysis of Technologically Mediated Interaction.” Sociology 37 (3): 581–589.
Innovate UK. 2018. Establishing UK Treatment Centres for Advanced Therapies. Accessed June 11, 2018. https://assets.
publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/ﬁle/677100/Establishing_UK_
Treatment_Centres_For_Advanced_Therapies_-_Competition_Results.pdf.
Kern, F. 2012. “Using the Multi-Level Perspective on Socio-Technical Transitions to Assess Innovation Policy.”
Technological Forecasting and Social Change 79: 298–310.
Khalil, O. E. 2011. “e-Government Readiness: Does National Culture Matter?” Government Information Quarterly 28 (3):
388–399.
Kuo, K.-M., C.-F. Liu, and C.-C. Ma. 2013. “An Investigation of the Eﬀect of Nurses’ Technology Readiness on the
Acceptance of Mobile Electronic Medical Record Systems.” BMC Medical Informatics and Decision Making 13: 88.
Law, J. 2010. “The Materials of STS.” In The Oxford Handbook of Material Cultural Studies, edited by D. Hicks and M. C.
Beaudry, 173–188. Oxford: OUP.
Lee, M.-C., T. Chang, and W.-T. Chien. 2011. “An Approach for Developing Concept of Innovation Readiness Levels.”
International Journal of Managing Information Technology (IJMIT) 3 (2): 18–37.
Malerba, F. 2002. “Sectoral Systems of Innovation.” Research Policy 31 (2): 247–264.
Mankins, J. 2009. “Technology Readiness Assessments: A Retrospective.” Acta Astronautica 65: 1216–1223.
Martin, S., and J. Scott. 2000. “The Nature of Innovation Market Failure and the Design of Public Support for Private
Innovation.” Research Policy 29 (4–5): 437–447.
May, C. R., T. Finch, L. Ballini, A. MacFarlane, F. Mair, E. Murray, and T. Rapley. 2011. “Evaluating Complex Interventions and
Health Technologies using Normalization Process Theory: Development of a Simpliﬁed Approach and Web-Enabled
Toolkit.” BMC Health Services Research 11 (1): 245–285.
Meijer, A. 2015. “E-governance Innovation: Barriers and Strategies.” Government Information Quarterly 32 (2): 198–206.
1240 A. WEBSTER AND J. GARDNER
Mohnen, P., F. Palm, S. van der Loeﬀ, and A. K. Tiwari. 2008. “Financial Constraints and Other Obstacles: Are they a Threat
to Innovation Activity?” De Economist 156: 201–214.
Nakamura, H., Y. Kajikawa, and S. Suzuki. 2012. “Multi-level Perspectives with Technology Readiness Measures for Aviation
Innovation.” Sustainability Science 8 (1): 87–101.
NASA. 2007. NASA Systems Engineering Handbook. Washington, DC: National Aeronautics and Space Administration.
NDA. 2014. Guide to Technology Readiness Levels for the NDA Estate and its Supply Chain. London: Nuclear
Decommissioning Authority.
Nelson, R. R. 1994. “The Co-evolution of Technology, Industrial Structure, and Supporting Institutions.” Industrial and
Corporate Change 3: 47–63.
NHS. 2018. Digital Maturity Index. UK: National Health Service. https://www.england.nhs.uk/digitaltechnology/info-
revolution/maturity-index/.
Nilsen, P. 2015. “Making Sense of Implementation Theories, Models and Frameworks.” Implementation Science 10. doi:10.
1186/s13012-015-0242-0.
Olechowski, A., S. D. Eppinger, and N. Joglekar. 2015. “Technology Readiness Levels at 40: A Study of State-of-the-Art use,
Challenges, and Opportunities.” Proceedings of PICMET ‘15: Management of the Technology Age.
Papadaki, M. 2017. “Adaptation through Collaboration: Developing Novel Platforms to Advance the Delivery of Advanced
Therapies to Patients.” Frontiers in Medicine 4: 56.
Rogers, E. M. 1995. Diﬀusion of Innovations. 5th ed. New York: Free Press of Glencoe.
Rogers, E., S. Takegami, and J. Yin. 2001. “Lessons about Technology Transfer.” Technovation 21 (4): 253–261.
Rojas-Méndez, J. I., A. Parasuraman, and N. Papadopoulos. 2017. “Demographics, Attitudes, and Technology Readiness: A
Cross-Cultural Analysis and Model Validation.” Marketing Intelligence & Planning 35: 18–39.
Rotolo, D., D. Hicks, and B. Martin. 2015. What is an Emerging Technology? SPRU Working Paper Series (ISSN 2057-6668).
Shaw, E. K. 2012. “The Role of the Champion in Primary Care Change Eﬀorts: From the State Networks of Colorado
Ambulatory Practices and Partners (SNOCAP).” The Journal of the American Board of Family Medicine 25 (5): 676–685.
Sørensen, E. 2007. “The Time of Materiality.” Forum: Qualitative Social Research 8 (1): Art. 2.
Ulucanlar, S., A. Faulkner, S. Peirce, and G. Elwyn. 2013. “Technology Identity: The Role of Sociotechnical
Representationsin the Adoption of Medical Devices.” Social Science & Medicine 98: 95–105.
Willetts, D. 2013. Eight Great Technologies. London: HMSO.
TECHNOLOGY ANALYSIS & STRATEGIC MANAGEMENT 1241
